Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis

Abstract

Background: Large-scale and population-based studies of heart failure (HF) incidence and prevalence are scarce in China. The study sought to estimate the prevalence, incidence, and cost of HF in China. Methods: We conducted a population-based study using records of 50.0 million individuals ≥25 years old from the national urban employee basic medical insurance from 6 provinces in China in 2017. Incident cases were individuals with a diagnosis of HF (International Classification of Diseases code, and text of diagnosis) in 2017 with a 4-year disease-free period (2013–2016). We calculated standardized rates by applying age standardization to the 2010 Chinese census population. Results: The age-standardized prevalence and incidence were 1.10% (1.10% among men and women) and 275 per 100 000 person-years (287 among men and 261 among women), respectively, accounting for 12.1 million patients with HF and 3.0 million patients with incident HF ≥25 years old. Both prevalence and incidence increased with increasing age (0.57%, 3.86%, and 7.55% for prevalence and 158, 892, and 1655 per 100 000 person-years for incidence among persons who were 25–64, 65–79, and ≥80 years of age, respectively). The inpatient mean cost per-capita was $4406.8 and the proportion with ≥3 hospitalizations among those hospitalized was 40.5%. The outpatient mean cost per-capita was $892.3. Conclusions: HF has placed a considerable burden on health systems in China, and strategies aimed at the prevention and treatment of HF are needed. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: ChiCTR2000029094.

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials

“…The transition probability for CHD, death, and in-hospital death was 0.0854, 1.0763, and 2.5665%, respectively. Using the same formula, we could draw that the transition probabilities for HF and stroke were 0.0229 and 0.0288%, and the transition probabilities for death and inhospital death for HF and stroke were 0.5368 vs. 0.8632% and 2.7683 vs. 1.5447% (Table 1) (20,21,23).…”

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review

“…Studies reported that approximately 12 million Chinese adults suffered from HF and estimated that the prevalence of HF would keep rising ( Wang, 2017 ; Hao et al, 2019 ). In 2017, the estimated average annual hospitalization cost for HF was $4,406.8 per patient, and the cost of all drugs accounted for 30.6% of the total medical expenses ( Wang et al, 2021 ). In recent years, several studies have proved the effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of patients with HF.…”

Development of Core Educational Content for Heart Failure Patients in Transition from Hospital to Home Care: A Delphi Study

“…Several recent reports have emphasized that heart failure (HF) is a major global health problem, in that the overall number of people including older adults with HF has increased due to considerable increases in predisposing diseases or comorbidities [ 1 , 2 , 3 ]. Likewise, the incidence of patients with HF in South Korea was estimated to be 1.53% in 2013 and is expected to increase by 2.2-fold to 3.4% by 2040 [ 4 ].…”